Chaga Mushroom (Inonotus obliquus)
Chaga Mushroom (Inonotus obliquus)
Chaga Mushroom (Inonotus obliquus) is a parasitic fungus native to the boreal birch forests of the Northern Hemisphere. It grows not as a conventional mushroom but as a hard, charcoal-black conk erupting from the bark of living birch trees — the product of a slow, decades-long battle between fungus and host. That host-parasite chemistry is the source of chaga's most valued bioactive compounds, which cannot be replicated in any lab-grown substrate.
Inonotus obliquus (Ach. ex Pers.) Pilát — Hymenochaetaceae — Hymenochaetales
Chaga Mushroom (Inonotus obliquus) has been used in Slavic and Siberian folk medicine for over five centuries — against gastric cancer, tuberculosis, and gastrointestinal disease — long before any laboratory evaluated a single compound it contains. First formally described in 1801 by Christian Hendrik Persoon and placed in the genus Inonotus by Albert Pilát in 1942, it is today one of the most commercially significant medicinal fungi in the world. It is also one of the most misunderstood: widely sold as a "mushroom," often marketed with inflated compound claims, and subject to a growing adulteration crisis in the supplement industry. This guide covers the science accurately.
Interested in this species? Out-Grow carries a liquid culture.
Chaga Mushroom (Inonotus obliquus) Liquid CultureWhat Is Chaga Mushroom (Inonotus obliquus)?
The Chaga Mushroom (Inonotus obliquus) is technically not a mushroom at all. The structure harvested and consumed as chaga is a sterile sclerotium — sometimes called a sterile conk or pseudosclerotium — a hardened mass of fungal mycelium and decayed woody host tissue that erupts through birch bark over the course of many years. Only about 10% of its mass is fungal mycelium; the rest is degraded wood from the host tree. The true spore-bearing fruiting body is a separate, flat, crust-like structure that forms briefly under the bark of dead trees after the host dies — and is almost never observed in the field.
Calling it a "chaga mushroom" is an informal but universally accepted convention — one with more than 500 years of documented use in Slavic ethnomycology, where the Russian word "чага" (chaga) has been in continuous use. The term has been adopted without meaningful variation into English, French, German, and Spanish, and appears routinely in peer-reviewed scientific literature. Using it does not misrepresent the organism; it simply reflects how the world has always talked about it.
What makes the Chaga Mushroom (Inonotus obliquus) biologically extraordinary is its obligate dependence on a living, actively defending host tree. Unlike virtually every other commercially relevant medicinal fungus — lion's mane, reishi, turkey tail, shiitake — chaga cannot produce its characteristic bioactive chemistry on dead substrate. The host birch tree's immune response to fungal invasion is, paradoxically, a co-producer of the compounds that make chaga valuable. Lab-grown mycelium, as comprehensively documented in a 2025 multi-analytical study, lacks the triterpenoids, melanins, and characteristic markers that define authentic wild chaga.
The name Inonotus obliquus encodes this biology: obliquus (Latin: oblique) refers to the 20–30° angle of the pores in the fertile basidiocarp. The genus name derives from Greek roots meaning "fibrous ear," referencing the woody texture of these bracket-forming fungi.
How Is Chaga Mushroom (Inonotus obliquus) Classified?
| Rank | Name |
|---|---|
| Kingdom | Fungi |
| Phylum | Basidiomycota |
| Class | Agaricomycetes |
| Order | Hymenochaetales |
| Family | Hymenochaetaceae |
| Genus | Inonotus |
| Species | Inonotus obliquus (Ach. ex Pers.) Pilát, 1942 |
| NCBI Taxonomy ID | 34617 · FDA UNII: MPJ44C2S19 |
The basionym is Boletus obliquus Ach. ex Pers. (1801), described by Christian Hendrik Persoon from material supplied by Erik Acharius. In the 19th century, Fries validated the name as Polyporus obliquus, and subsequent taxonomists placed it variously in Poria, Phellinus, and Fuscoporia — the last still encountered in some Chinese and Japanese mycological literature. In 1942, Albert Pilát recombined it in Inonotus, where it remains today. The correct full author citation is (Ach. ex Pers.) Pilát.
The Chaga Mushroom (Inonotus obliquus) belongs to the order Hymenochaetales (literally "mane-bristle" fungi) — a large clade of predominantly wood-decay basidiomycetes united by the absence of clamp connections, brown-pigmented cell walls, and abundant skeletal hyphae. Within this order, I. obliquus is most closely related to Fomitiporia mediterranea and the Sanghuang mushroom (Sanghuangporus baumii), both of which share the parasitic wood-decay lifestyle and some secondary metabolite chemistry.
How Do You Identify Chaga Mushroom (Inonotus obliquus)?
The Sterile Conk — What Is Actually Harvested
The single most reliable field identification feature of Chaga Mushroom (Inonotus obliquus) is the contrast between its intensely black, charcoal-like exterior and its rusty-orange to orange-brown interior. No other common birch conk shares this color combination. The black exterior is caused by allomelanins — a specific class of melanins derived from catechol precursors that are uniquely concentrated in this species.
The fertile basidiocarp — the true spore-releasing structure — forms as a flat, resupinate (crust-like) bracket up to 3–4 m long on the underside of detached bark of dead or dying host trees. It is grayish-brown, bears oblique downward-cascading pores, and desiccates and disintegrates within weeks of formation. Most experienced mycologists never observe it in the wild.
Lookalike Species
Fomes fomentarius — Hoof Fungus / Tinder Conk
Most commonly confused with chaga. Grows on birch but has a classic hoof-shape with distinct concentric bands, a grey-to-brown exterior, and a brown (not orange) interior. No charcoal-black cracked surface. Does not embed into wood — sits on the bark surface. Widely misidentified as chaga in popular media.
Phellinus nigricans
Black exterior, grows on birch — the closest visual match. Distinguished by a flatter, more even surface profile, a visible pore surface on the underside, and smaller conks. Does not produce the characteristic orange-brown interior of authentic chaga.
Inonotus hispidus
Same genus. Rust-colored (not black) exterior; clearly a fruiting body morphology with visible bracket form; found on oak and ash rather than birch; hairy surface texture. Unlikely to cause genuine field confusion but included for completeness.
Phellinus tremulae
Dull grey-brown; horse-hoof shape; found primarily on aspen and occasionally birch. Lacks the black charcoal exterior and orange interior of I. obliquus. No significant medicinal use or commercial value.
Where Does Chaga Mushroom (Inonotus obliquus) Grow?
The Chaga Mushroom (Inonotus obliquus) has a circumpolar boreal and temperate distribution, following the range of its primary host — birch (Betula spp.) — across the Northern Hemisphere. Approximately 90% of documented occurrence records involve birch, with the fungus preferring mature trees aged 30–80 years. Younger trees are rarely infected; very old trees are sometimes too weakened to sustain the long parasitic relationship. Infection occurs through established bark wounds from pruning, lightning, frost cracks, or prior pathogen damage.
| Region | Status / Notes |
|---|---|
| Russia (Siberia, Karelia, Ural, Kamchatka) | Widest range and densest populations; traditional wild-harvest epicenter; Altai, Khanty-Mansiysk among richest areas |
| Scandinavia (Finland, Sweden, Norway) | Finland has harvesting quotas; estimated sustainable national wild harvest ~44,000 lbs/year — industry participants describe this as insufficient for commercial demand |
| Eastern Europe (Poland, Belarus, Baltics, Czech Republic, Romania, Bulgaria) | Poland: legally protected, cannot be harvested without special permit; Belarus: major export source |
| East Asia (Japan, South Korea, China — Heilongjiang, Shanxi, Shandong) | Active commercial use; China is a major producer of cultivated mycelium products |
| North America (northeastern USA, Quebec, Ontario, British Columbia) | Maine, Vermont, Michigan, Wisconsin, Minnesota; Canadian provinces; growing forager interest |
| Western/Central Europe (Germany, France, UK) | Present but rarer; UK records genuine but sparse |
The sterile conk is present and harvestable year-round. The absence of foliage in late autumn through early spring makes visual detection easiest during those months. The fertile basidiocarp forms only briefly during the warm season on recently dead host wood and is rarely observed.
Can You Cultivate Chaga Mushroom (Inonotus obliquus)?
This is the most important and most frequently misrepresented question about the Chaga Mushroom (Inonotus obliquus). The honest answer has two parts. The wild-equivalent sclerotium — the charcoal-black conk with its full complement of triterpenoids, melanins, and characteristic markers — cannot be produced without a living host tree. What can be produced in laboratory conditions is mycelial biomass, which has a substantially different and less complete chemical profile.
Why the Sterile Conk Requires a Living Tree
The sclerotium is not simply a fungal structure — it is a boundary formed at the interface of host defense and fungal invasion. The tree's immune response to I. obliquus colonization plays a direct role in inducing the sclerotium and in producing the host-derived compounds (betulin, betulinic acid precursors) that give wild chaga its unique chemistry. On dead wood, I. obliquus is typically outcompeted by saprotrophic fungi — Fomes fomentarius, Trametes versicolor — before a sclerotium can form. The molecular signaling between host defense and sclerotium initiation is not yet understood, which is precisely why no in vitro induction protocol exists.
Living Tree Inoculation — The Only Path to Wild-Equivalent Chaga
Host Selection
Choose living birch trees aged 30–50 years. Trees should be healthy but can have some existing stress. Very young trees (<15 years) are rarely receptive. Betula pendula and B. platyphylla var. japonica are the best-documented hosts in inoculation studies.
Inoculation Method
Drill holes through bark into sapwood; inoculate with spawn (grain, plug, or liquid culture). Standard depth 3–5 cm. Seal with wax or tape to prevent desiccation and competing fungal entry. Spring or early summer inoculation is preferred.
Colonization Phase
The fungus must establish in living heartwood before any external sign appears. Published studies report 62% infection rate (fungus internal) but only ~4% sclerotium formation externally — the fungus may grow internally without producing a visible conk.
Timeline to Harvest
Minimum 5–6 years to a harvestable conk; commercial operations plan for 9–10 years. Finnish biotech company KÄÄPÄ Biotech has developed semi-commercial living-birch inoculation networks representing the cutting edge of controlled chaga production.
Agar Culture Behavior
The Chaga Mushroom (Inonotus obliquus) grows on agar but is notably slow compared to most cultivated species. Peer-reviewed data show growth rates of 2.18 mm/day on PDA under standard conditions, increasing to 3.60 mm/day when hydrolysed lignin (Polyphepan) is added to the medium. Colony morphology progresses from white to cream initially, acquiring yellowish to olive-tan coloration, with brown melanin pigmentation developing after approximately 8 days on established cultures. Aerial mycelium is typically sparse.
Optimal temperature varies by strain provenance: boreal strains from Scandinavia grow best at 16°C; temperate-zone strains from Russia and Korea perform best at 25–30°C. This reflects genuine geographic adaptation, not experimental inconsistency. PDA and yeast extract agar (YA) outperform other tested media; birch-based agar performs poorly despite the species' host preference.
Liquid Culture / Submerged Fermentation
Submerged fermentation is well-documented for mycelial biomass production. The most detailed peer-reviewed protocol (Chen et al. 2024, Foods) used an 18°C, 125 rpm seed culture followed by scale-up in a 10 L fermentor at 18°C for 30 days. With controlled atmosphere treatment (50% N₂ / 50% O₂), polysaccharide content reached 9.17 mg/g and betulinic acid reached 1.96 mg/g — a 2.2-fold and 2.8-fold improvement over normal air conditions respectively. DPPH free-radical scavenging reached 87.32% at day 30, with culture quality declining after this point.
What Out-Grow's Liquid Culture Is For
Out-Grow's Chaga Mushroom (Inonotus obliquus) liquid culture is an actively growing mycelium suspension in sterile nutrient solution. Its primary applications are agar expansion (rapidly colonizing fresh plates for culture banking), spawn production for living-tree inoculation projects, mycelial biomass production for research or supplement extraction, and experimental fermentation work.
The liquid culture will not produce a sclerotium or wild-equivalent chemistry on any dead substrate — this is a biological constraint of the species, not a limitation of the culture itself. What it provides is a viable, genetically authentic isolate of I. obliquus ready to work with immediately, without the slow agar-based initiation typical of this species.
Contamination vigilance is particularly important with this species: I. obliquus's slow growth rate (2–3 mm/day on agar) makes it more vulnerable to fast-growing contaminants like Trichoderma spp. than faster-colonizing species. Strict sterile technique and transfer from clean, uncontaminated cultures is essential.
What Bioactive Compounds Does Chaga Mushroom (Inonotus obliquus) Contain?
The Chaga Mushroom (Inonotus obliquus) is chemically complex, with its compound profile distributed across several distinct structural classes. Critically, the full chemistry profile applies specifically to the wild sterile sclerotium. Lab-grown mycelium has a different and substantially incomplete profile — as detailed in the Cultivation section above. All compound data below refer to wild canker unless stated otherwise.
β-Glucans (β-1,3/β-1,6)
Primary immunomodulatory compounds. Wild canker contains 5.7–11.9% β-glucans (Megazyme assay). Activate macrophages, NK cells, and stimulate cytokine production (TNF-α, IL-2, IL-6, IL-12) in animal and in vitro models. Supplement claims of 30–45% β-glucan should be viewed with strong skepticism — such values likely reflect cereal β-glucans from grain substrate, not fungal glucans.
Inotodiol
Lanostane-type triterpenoid present at ~0.19% w/w in wild canker. In vitro: decreases MMP-2 and MMP-9 expression in HeLa cells; induces apoptosis via caspase-3 activation. A reliable chemical authentication marker for genuine wild chaga — absent in liquid culture mycelium and grain-grown mycelium.
Trametenolic Acid
Triterpenoid at ~0.09% w/w in wild canker. Documented anti-inflammatory activity; cytotoxic against PC3 prostate and MDA-MB-231 breast cancer cell lines in vitro. Absent in lab-grown mycelium and therefore a useful authentication marker distinguishing wild chaga from cultivated products.
Ergosterol Peroxide
Fungal sterol derivative. Downregulates the β-catenin pathway in colorectal cancer cells in vitro; anti-inflammatory activity documented. Present in wild canker and to some extent in mycelium, as ergosterol (the precursor) is a general fungal membrane component.
Allomelanins
The compound class responsible for chaga's characteristic black exterior. Produced from catechol/polyphenol precursors — chemically distinct from animal melanins (tyrosine-derived) and from the eumelanins produced by chaga mycelium in submerged fermentation. Potent free-radical scavengers; immunomodulatory. Negligible in any lab-grown product — a reliable wildness marker.
3,4-Dihydroxybenzalacetone (DBL)
Described as a primary antioxidative phenolic in multiple papers. Neuroprotective in Parkinson's and Alzheimer's cell models via Akt/Nrf2/glutathione pathway activation. Demonstrated cell-to-cell propagation of antioxidant effects via extracellular vesicles in neuroblastoma cells. One of chaga's more mechanistically interesting phenolics.
Chlorogenic Acid & Phenolics
Most abundant quantified phenolic: 641–971 mg/kg extract (method-dependent). Total phenolics reach 39.32 mg GAL/g DW under optimal extraction (170°C, 66% ethanol). Total antioxidant capacity is 8× higher than all other mushrooms tested in one comparative Manitoba study. Also: syringic acid, vanillic acid, ferulic acid, gallic acid, protocatechuic acid, caffeic acid.
Betulinic Acid
Anti-tumor (suppresses 4T1 breast cancer mouse model; reduces MMP-9 and Ki-67); anti-HIV; anti-inflammatory. Sourced from the fungus's biotransformation of host birch betulin. Notably, a rigorous 2025 multi-analytical study did not detect betulin or betulinic acid in wild canker samples — contradicting older literature. Its presence may be geographically variable or analytical-method dependent. Absent in lab-grown mycelium on non-birch substrates.
Is Chaga Mushroom (Inonotus obliquus) Safe?
The Chaga Mushroom (Inonotus obliquus) has a long folk-use record with no documented intrinsic toxins, and for most people consuming standard amounts, no adverse effects have been reported. However, chaga carries a specific, documented, and serious risk that receives inadequate attention in popular coverage: oxalate nephropathy.
Oxalate Nephropathy — Documented Kidney Injury
Chaga contains extremely high levels of oxalic acid: measured at 14.2 g per 100 g dry weight in Korean material, and 3,904 mg/kg soluble oxalates in North American material. At high doses — particularly above 10 g/day — this oxalate load can overwhelm normal urinary excretion capacity, causing calcium oxalate crystals to deposit in renal tubules, triggering inflammation, tubular necrosis, and in severe cases permanent fibrosis. Three published case reports document serious outcomes:
| Case | Exposure | Outcome |
|---|---|---|
| 49-year-old man (Korea, 2020) | Long-term chaga consumption | End-stage renal disease (ESRD); biopsy confirmed chronic tubulointerstitial nephritis with oxalate crystals |
| 69-year-old man | 10–15 g/day + 500 mg Vitamin C for 3 months | Acute kidney injury with nephrotic syndrome; required hemodialysis and high-dose steroids; recovery after 1 month of treatment |
| 72-year-old patient | ~4–5 teaspoons/day (~10–15 g) for 6 months | Acute oxalate nephropathy requiring hemodialysis; diffuse tubular atrophy and interstitial fibrosis on biopsy |
Risk factors that increase vulnerability: pre-existing kidney disease or reduced renal function, doses above 10 g/day, co-ingestion of high-dose vitamin C (which metabolizes to oxalate, adding to the load), dehydration, and a personal history of calcium oxalate kidney stones. For the general population consuming standard doses of 1–5 g/day, the risk is low but not zero — and no dose-response safety study has established a definitive lower-bound safe intake threshold.
Drug Interactions (Preclinical Evidence Only)
No human pharmacokinetic drug interaction studies exist. Based on preclinical data: chaga extracts showed antiplatelet activity in rodent studies (theoretical additive risk with warfarin or aspirin); hypoglycemic activity in diabetic rat models (theoretical additive effect with insulin or metformin); and immunostimulatory polysaccharide activity that could theoretically oppose immunosuppression in transplant patients. None of these interactions have been confirmed in humans.
What Makes Chaga Mushroom (Inonotus obliquus) Remarkable?
A Living Co-Production Between Pathogen and Host
The Chaga Mushroom (Inonotus obliquus) is one of the only commercially important fungi whose most valued bioactive compounds are not produced by the fungus alone — they require the living host tree as a chemical co-producer. The fungus converts betulin from birch bark into betulinic acid through enzymatic biotransformation — a pharmacologically more active derivative that lab-grown mycelium on non-birch media simply cannot produce. The host's immune response to fungal invasion simultaneously induces the sclerotium's formation and contributes to the accumulation of allomelanins and terpenoids in the boundary tissue. The tree's defense and the fungus's chemistry are biologically inseparable — which is why no substitute for the living-host relationship has been found despite decades of effort.
A Dual Melanin System Found Nowhere Else
Wild chaga sclerotia contain allomelanins — produced from catechol/polyphenol precursors, responsible for the charcoal-black exterior, and potent free-radical scavengers. Chaga mycelium grown in submerged fermentation produces eumelanins — produced through a different biosynthetic pathway and with different spectroscopic signatures. These are chemically distinct compounds with different biological properties in the same organism — a feature unique among commonly used medicinal fungi, and one that makes allomelanin content a reliable authentication marker for genuine wild chaga. No commercially cultivated mushroom product contains allomelanins at meaningful levels.
The Invisible Reproductive Event
The fertile, spore-bearing basidiocarp of the Chaga Mushroom (Inonotus obliquus) is one of the least-observed sexual structures in commercially relevant mycology. It forms as a flat, crust-like bracket — up to 3–4 meters long — under detached bark of dead or dying host trees during the warm season, releases spores, and then rapidly desiccates and disintegrates, the entire event potentially lasting only weeks. Most experienced field mycologists never observe it. During this brief window, approximately 400 documented species of forest-dwelling moths and insects have been recorded feeding on the spores — making the chaga reproductive event an entire transient ecosystem. Complete removal of the sterile conk before host death may interrupt this cycle and reduce local spore dispersal, contributing to population decline in heavily harvested areas.
A Genome Built for Chemical Warfare
The 2022 first de novo assembled genome of I. obliquus (38.18 Mb; 12,525 protein-coding genes) revealed a secondary metabolite biosynthetic capacity disproportionate to its genome size: 135 cytochrome P450 enzymes (the molecular machinery for terpenoid and sterol transformation), 20 sesquiterpenoid synthases with four distinct cyclization mechanisms, and 13 putative terpenoid biosynthesis gene clusters. This enzymatic richness explains the extraordinary diversity of triterpenoids and sterols that characterize wild chaga chemistry — and suggests the fungus has evolved specialized chemical warfare tools for surviving the living host's defense response over decades of parasitic growth.
The Supplement Adulteration Crisis
The 2025 Nammex/PurityIQ multi-analytical study documented what many in the industry had long suspected: some commercial products labeled as "chaga" have NMR spectra nearly identical to their grain substrate — meaning consumers may be purchasing primarily oats or rice labeled as chaga. Mycelium-on-grain products can contain 33–68% α-glucan (starch) from the grain substrate, no melanin, no inotodiol, no trametenolic acid, and no osmundacetone. Reliable markers for authentic wild chaga include: <2% α-glucan, presence of inotodiol and trametenolic acid by LC-MS, high allomelanin absorbance, and negative Lugol's starch test. The absence of standardized authentication criteria in the chaga supplement industry is arguably its most consequential quality control problem.
Frequently Asked Questions About Chaga Mushroom (Inonotus obliquus)
Is Chaga Mushroom (Inonotus obliquus) actually a mushroom?
Technically, no. The structure harvested as chaga is a sterile sclerotium — a hardened mass of fungal mycelium and decayed host wood that erupts from living birch bark. It produces no spores and has no cap, gills, or pore surface. The true spore-bearing fruiting body is a separate, flat, crust-like structure that forms briefly after the host tree dies and is almost never observed in the wild. "Chaga mushroom" is a universally accepted colloquial designation with over 500 years of documented use — using it doesn't misrepresent the organism, but understanding what chaga actually is helps explain why it can't be conventionally cultivated.
Can Chaga Mushroom (Inonotus obliquus) be cultivated?
The wild-equivalent sclerotium cannot be produced without a living host tree — this is a confirmed biological constraint, not a knowledge gap. The sclerotium forms at the host-pathogen boundary, partly induced by the tree's own immune response. On dead substrate, I. obliquus is outcompeted before a conk can form. Living-tree inoculation is the only documented pathway to wild-equivalent chaga, with published studies achieving ~4% external sclerotium formation from inoculated trees on a 5–10 year timeline. Mycelial biomass can be produced in liquid culture or submerged fermentation, but its chemical profile is substantially different from wild canker.
What is the difference between wild Chaga Mushroom (Inonotus obliquus) and lab-grown mycelium?
Wild chaga canker contains the species' full chemical complement: 5.7–11.9% β-glucans, characteristic triterpenoids (inotodiol, trametenolic acid, lanosterol), allomelanins, and host-derived compounds. Lab-grown liquid culture mycelium contains β-glucans but no melanin and no signature triterpenoids. Grain-grown mycelium ("mycelium on grain") contains primarily starch from the grain substrate — up to 68% α-glucan — and minimal fungal chemistry. A 2025 multi-analytical study confirmed that no lab-grown substrate produces chemistry equivalent to wild canker.
Is Chaga Mushroom (Inonotus obliquus) safe to consume?
For most people at standard doses (1–5 g/day), no adverse effects have been documented beyond the oxalate nephropathy cases below. However, chaga has an extremely high oxalate content (up to 14.2 g per 100 g dry weight), and three published case reports document serious kidney injury — including end-stage renal disease and acute nephropathy requiring hemodialysis — in people consuming 10–15 g/day, particularly when combined with high-dose vitamin C. People with existing kidney disease, kidney stones, or reduced renal function should consult a physician before using chaga. No safe dose-response data have been established.
What human clinical evidence exists for Chaga Mushroom (Inonotus obliquus)?
As of March 2026, there are no published randomized controlled trials, Phase I/II/III clinical studies, or rigorous controlled observational studies in humans demonstrating efficacy of Inonotus obliquus for any medical indication. Two uncontrolled Soviet-era studies exist — one in 50 psoriasis patients and one in 58 peptic ulcer patients — both using the Russian pharmaceutical preparation Befungin, neither of which meets modern evidentiary standards. All current evidence for chaga's health activities is in vitro (cell culture) or animal model level.
What is a liquid culture used for in Chaga Mushroom (Inonotus obliquus) research and cultivation?
Liquid culture provides a viable, actively growing suspension of I. obliquus mycelium for agar expansion and culture banking, spawn production for living-tree inoculation, mycelial biomass production for research or supplement extraction, and experimental fermentation projects. It bypasses the slow agar-based initiation typical of this species and delivers a genetically authentic isolate ready to work with immediately. It will not produce a sclerotium or wild-equivalent chemistry on any dead substrate — that requires a living birch host — but it is the correct starting point for any serious cultivation or research use of this species.
Also available as a culture plate from Out-Grow.
Chaga Mushroom (Inonotus obliquus) Culture Plate